DGAT2 and hypertriglyceridemia: Inhibition of DGAT2 expression has been shown to improve insulin resistance and hepatic steatosis in T2DM rats, suggesting that DGAT2 plays an important role in hepatic steatosis and hypertriglyceridemia in T2DM (Choi et al., 2007; Zhang et al., 2019).